Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: AnaptysBio is a clinical-stage biotechnology company developing immune cell modulating antibodies for autoimmune and inflammatory diseases. Key wholly-owned candidates include rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist). The company also generates revenue through a collaboration with GlaxoSmithKline (GSK) regarding immuno-oncology assets (Jemperli and Zejula).
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Collaboration Revenue | $10,971 | $18,150 | $4,834 |
| Total Operating Expenses | $51,292 | $100,672 | $89,378 |
| Net Loss | $(46,660) | $(90,596) | $(84,100) |
| Net Loss Per Share (Basic & Diluted) | $(1.71) | $(3.35) | $(3.08) |
| Cash, Cash Equivalents & Investments | $393,500 (as of June 30, 2024) | ||
| Liability for Sale of Future Royalties | $361,981 (as of June 30, 2024) |
Liquidity: As of June 30, 2024, the company held $71.8 million in cash and cash equivalents and $321.6 million in short-term and long-term investments. Management believes current resources are sufficient to fund operations for at least the next twelve months.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased significantly to $18.2 million for the six months ended June 30, 2024, compared to $4.8 million in the prior year period. This increase is primarily driven by higher royalty revenues from GSK's net sales of Jemperli and Zejula.
- Operating Expenses: Total operating expenses rose to $100.7 million (6 months 2024) from $89.4 million (6 months 2023). Research and Development (R&D) expenses increased by $11.2 million, driven by a $17.7 million increase in clinical expenses for rosnilimab and ANB032, partially offset by a decrease in manufacturing costs.
- Non-Cash Interest Expense: Non-cash interest expense related to the sale of future royalties increased to $17.3 million (6 months 2024) from $8.7 million (6 months 2023). This increase is attributed to the May 2024 amendment to the Jemperli Royalty Monetization Agreement, which increased the threshold amounts of royalties to be received by the monetization partner.
- Net Loss: Net loss widened to $90.6 million for the six months ended June 30, 2024, compared to $84.1 million in the prior year period, reflecting increased R&D spend and non-cash interest costs.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Rosnilimab: Top-line data for the Phase 2b trial in rheumatoid arthritis (RA) is expected in Q1 2025. Top-line data for the Phase 2 trial in ulcerative colitis (UC) is expected in Q1 2026.
- ANB032: Top-line data for the Phase 2b trial in atopic dermatitis (AD) is expected in December 2024.
- ANB033 & ANB101: Phase 1 trials are anticipated to begin in Q4 2024.
- Out-Licensing: The company intends to out-license imsidolimab (GPP) and etokimab in 2024.
Key Risks and Contingencies:
- Capital Requirements: The company has a history of losses and will require additional capital to fund operations beyond the next 12 months. There is no assurance that financing will be available on acceptable terms.
- Development Risk: Product candidates are in clinical stages and may fail to demonstrate safety or efficacy in future trials.
- Collaboration Dependence: Revenue is heavily dependent on the GSK collaboration. Termination or de-prioritization of GSK programs would materially impact the business.
- Royalty Monetization: The company has sold future royalty rights for Jemperli and Zejula. While this provides immediate liquidity, it limits future upside and creates significant non-cash interest expenses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $393.5 million cash position against the projected burn rate, considering the significant increase in R&D clinical expenses.
- Royalty Monetization Terms: Review the specific terms of the May 2024 Jemperli Amendment to understand the impact on future royalty thresholds and the resulting non-cash interest expense trajectory.
- Clinical Trial Timelines: Monitor the upcoming data readouts for ANB032 (Dec 2024) and rosnilimab (Q1 2025) as critical catalysts for valuation.
- Out-Licensing Progress: Track the status of potential out-licensing deals for imsidolimab and etokimab, which could provide non-dilutive capital.
- Stock-Based Compensation: Note the $17.7 million in stock-based compensation expense for the six-month period and its impact on future dilution.